Document is current
Any future updates will be listed below
-
Authors
Conteduca, Vincenza https://orcid.org/0000-0002-6921-714X
Brighi, Nicole
Schepisi, Giuseppe https://orcid.org/0000-0002-9973-4869
De Giorgi, Ugo https://orcid.org/0000-0001-7520-2908
- License Information
-
More Information
Article History
Received: 12 December 2022
Revised: 18 June 2023
Accepted: 28 June 2023
First Online: 13 July 2023
Competing interests
: VC has served as a consultant/advisory board member for Janssen, Astellas, Merck, AstraZeneca, Amgen, EISAI, Recordati and Bayer and has received speaker honoraria or travel support from Astellas, Janssen, Ipsen, Bayer, Gilead and BristolMyers Squibb. UDG reports research support from AstraZeneca, Roche and Sanofi; and consultancy fees from Astellas, Bayer, BristolMyers Squibb, Ipsen, Janssen, Merck, Pfizer and Sanofi. No potential conflicts of interest were disclosed by the other authors.
: This work does not require any ethics approval or participating consent.
: Not applicable.
